Valdipromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314376

CAS#: 52061-73-1

Description: Valdipromide is a biochemical.

Chemical Structure

img
Valdipromide
CAS# 52061-73-1
Instruction

Theoretical Analysis

MedKoo Cat#: 314376
Name: Valdipromide
CAS#: 52061-73-1
Chemical Formula: C11H23NO
Exact Mass: 185.18
Molecular Weight: 185.311
Elemental Analysis: C, 71.30; H, 12.51; N, 7.56; O, 8.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Valdipromide;

IUPAC/Chemical Name: 2,2-Dipropylvaleramide

InChi Key: ACBLZFZDCOGNHD-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H23NO/c1-4-7-11(8-5-2,9-6-3)10(12)13/h4-9H2,1-3H3,(H2,12,13)

SMILES Code: CCCC(CCC)(CCC)C(N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 185.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Foch C, Araujo M, Weckel A, Damase-Michel C, Montastruc JL, Benevent J, Durrieu G, Lacroix I. In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database. Int J Pediatr Otorhinolaryngol. 2018 Oct;113:192-197. doi: 10.1016/j.ijporl.2018.07.035. Epub 2018 Jul 24. PubMed PMID: 30173984.

2: Li CW, Jheng BR, Chen BS. Investigating genetic-and-epigenetic networks, and the cellular mechanisms occurring in Epstein-Barr virus-infected human B lymphocytes via big data mining and genome-wide two-sided NGS data identification. PLoS One. 2018 Aug 22;13(8):e0202537. doi: 10.1371/journal.pone.0202537. eCollection 2018. PubMed PMID: 30133498; PubMed Central PMCID: PMC6105016.

3: Fond G, Resseguier N, Schürhoff F, Godin O, Andrianarisoa M, Brunel L, Bulzacka E, Aouizerate B, Berna F, Capdevielle D, Chereau I, D'Amato T, Dubertret C, Dubreucq J, Faget C, Gabayet F, Lançon C, Llorca PM, Mallet J, Misdrahi D, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Boyer L, Leboyer M; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. 2018 Sep;268(6):541-553. doi: 10.1007/s00406-017-0847-1. Epub 2017 Nov 10. PubMed PMID: 29127503.

4: Bahna SG, Niles LP. Epigenetic regulation of melatonin receptors in neuropsychiatric disorders. Br J Pharmacol. 2017 Oct 2. doi: 10.1111/bph.14058. [Epub ahead of print] Review. PubMed PMID: 28967098; PubMed Central PMCID: PMC6057907.

5: Kudin AP, Mawasi H, Eisenkraft A, Elger CE, Bialer M, Kunz WS. Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. Int J Mol Sci. 2017 Sep 6;18(9). pii: E1912. doi: 10.3390/ijms18091912. PubMed PMID: 28878165; PubMed Central PMCID: PMC5618561.

6: Bahna SG, Niles LP. Epigenetic induction of melatonin MT(1) receptors by valproate: Neurotherapeutic implications. Eur Neuropsychopharmacol. 2017 Aug;27(8):828-832. doi: 10.1016/j.euroneuro.2017.06.002. Epub 2017 Jun 22. PubMed PMID: 28648552.

7: Saenz-Méndez P, Katz A, Pérez-Kempner ML, Ventura ON, Vázquez M. Structural insights into human microsomal epoxide hydrolase by combined homology modeling, molecular dynamics simulations, and molecular docking calculations. Proteins. 2017 Apr;85(4):720-730. doi: 10.1002/prot.25251. Epub 2017 Feb 9. PubMed PMID: 28120429.

8: Fijałkowski Ł, Sałat K, Podkowa A, Zaręba P, Nowaczyk A. Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies. Eur J Pharm Sci. 2017 Jan 1;96:362-372. doi: 10.1016/j.ejps.2016.10.004. Epub 2016 Oct 6. PubMed PMID: 27721044.

9: Ornaghi S, Davis JN, Gorres KL, Miller G, Paidas MJ, van den Pol AN. Mood stabilizers inhibit cytomegalovirus infection. Virology. 2016 Dec;499:121-135. doi: 10.1016/j.virol.2016.09.012. Epub 2016 Sep 19. PubMed PMID: 27657833; PubMed Central PMCID: PMC5102808.

10: Rosa M, Bonnaillie P, Chanteux H. Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition. Xenobiotica. 2016 Dec;46(12):1076-1084. Epub 2016 Mar 3. PubMed PMID: 26936324.

11: Gorres KL, Daigle D, Mohanram S, McInerney GE, Lyons DE, Miller G. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus. MBio. 2016 Mar 1;7(2):e00113. doi: 10.1128/mBio.00113-16. PubMed PMID: 26933051; PubMed Central PMCID: PMC4810481.

12: Perrone M, Moon BS, Park HS, Laquintana V, Jung JH, Cutrignelli A, Lopedota A, Franco M, Kim SE, Lee BC, Denora N. A Novel PET Imaging Probe for the Detection and Monitoring of Translocator Protein 18 kDa Expression in Pathological Disorders. Sci Rep. 2016 Feb 8;6:20422. doi: 10.1038/srep20422. PubMed PMID: 26853260; PubMed Central PMCID: PMC4745082.

13: Eisses JF, Criscimanna A, Dionise ZR, Orabi AI, Javed TA, Sarwar S, Jin S, Zhou L, Singh S, Poddar M, Davis AW, Tosun AB, Ozolek JA, Lowe ME, Monga SP, Rohde GK, Esni F, Husain SZ. Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs. Am J Pathol. 2015 Dec;185(12):3304-15. doi: 10.1016/j.ajpath.2015.08.006. Epub 2015 Oct 23. PubMed PMID: 26476347; PubMed Central PMCID: PMC4729237.

14: Paradis FH, Hales BF. Valproic Acid Induces the Hyperacetylation of P53, Expression of P53 Target Genes, and Markers of the Intrinsic Apoptotic Pathway in Midorganogenesis Murine Limbs. Birth Defects Res B Dev Reprod Toxicol. 2015 Oct;104(5):177-83. doi: 10.1002/bdrb.21149. Epub 2015 Aug 25. PubMed PMID: 26305274.

15: Balasubramanian D, Deng AX, Doudney K, Hampton MB, Kennedy MA. Valproic acid exposure leads to upregulation and increased promoter histone acetylation of sepiapterin reductase in a serotonergic cell line. Neuropharmacology. 2015 Dec;99:79-88. doi: 10.1016/j.neuropharm.2015.06.018. Epub 2015 Jul 4. PubMed PMID: 26151765.

16: Ferrandi EE, Sayer C, Isupov MN, Annovazzi C, Marchesi C, Iacobone G, Peng X, Bonch-Osmolovskaya E, Wohlgemuth R, Littlechild JA, Monti D. Discovery and characterization of thermophilic limonene-1,2-epoxide hydrolases from hot spring metagenomic libraries. FEBS J. 2015 Aug;282(15):2879-94. doi: 10.1111/febs.13328. Epub 2015 Jun 16. PubMed PMID: 26032250.

17: Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13. Review. PubMed PMID: 25979572.

18: Groh T, Hrabeta J, Khalil MA, Doktorova H, Eckschlager T, Stiborova M. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int J Oncol. 2015 Jul;47(1):343-52. doi: 10.3892/ijo.2015.2996. Epub 2015 May 11. PubMed PMID: 25963435.

19: de Beaurepaire R, Trinh I, Guirao S, Taieb M. Colitis possibly induced by quetiapine. BMJ Case Rep. 2015 Feb 26;2015. pii: bcr2014207912. doi: 10.1136/bcr-2014-207912. PubMed PMID: 25721830; PubMed Central PMCID: PMC4342667.

20: Gabriel L, Darcissac C, Goutelle S, Sève P, Vial T, de La Gastine B. [Lower limb edema during valpromide treatment: case report and literature review]. Rev Med Interne. 2015 Oct;36(10):698-700. doi: 10.1016/j.revmed.2014.11.011. Epub 2014 Dec 24. Review. French. PubMed PMID: 25544148.